H Chih-Ho Hong

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2377209/publications.pdf

Version: 2024-02-01

43 papers 2,708 citations

430754 18 h-index 254106 43 g-index

45 all docs

45 docs citations

45 times ranked

2240 citing authors

#	Article	IF	CITATIONS
1	Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet, The, 2017, 389, 2287-2303.	6.3	884
2	A Comprehensive Approach to the Recognition, Diagnosis, and Severity-Based Treatment of Focal Hyperhidrosis: Recommendations of the Canadian Hyperhidrosis Advisory Committee. Dermatologic Surgery, 2007, 33, 908-923.	0.4	340
3	Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet, The, 2021, 397, 2151-2168.	6.3	259
4	Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial. Journal of Allergy and Clinical Immunology, 2020, 145, 877-884.	1.5	242
5	Dupilumab: A review of its use in the treatment of atopic dermatitis. Journal of the American Academy of Dermatology, 2018, 78, S28-S36.	0.6	218
6	Clinical Evaluation of a Microwave Device for Treating Axillary Hyperhidrosis. Dermatologic Surgery, 2012, 38, 728-735.	0.4	101
7	Phase 3 Trials of Tapinarof Cream for Plaque Psoriasis. New England Journal of Medicine, 2021, 385, 2219-2229.	13.9	93
8	Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis. JAMA Dermatology, 2022, 158, 404.	2.0	90
9	Treat-to-Target in Atopic Dermatitis: An International Consensus on a Set of Core Decision Points for Systemic Therapies. Acta Dermato-Venereologica, 2021, 101, adv00402.	0.6	45
10	Review of Systemic Treatment Options for Adult Atopic Dermatitis. Journal of Cutaneous Medicine and Surgery, 2017, 21, 31-39.	0.6	42
11	Efficacy and safety of guselkumab, administered with a novel patient-controlled injector (One-Press), for moderate-to-severe psoriasis: results from the phase 3 ORION study. Journal of Dermatological Treatment, 2020, 31, 152-159.	1.1	38
12	Long-term efficacy and quality of life assessment for treatment of axillary hyperhidrosis with a microwave device. Dermatologic Surgery, 2014, 40, 805-7.	0.4	30
13	Psoriasis Prevalence and Severity by Expert Elicitation. Dermatology and Therapy, 2021, 11, 1053-1064.	1.4	28
14	Approach to the Assessment and Management of Adult Patients With Atopic Dermatitis: A Consensus Document. Section II: Tools for Assessing the Severity of Atopic Dermatitis. Journal of Cutaneous Medicine and Surgery, 2018, 22, 10S-16S.	0.6	26
15	Optimizing the use of topical brimonidine in rosacea management: panel recommendations. Journal of Drugs in Dermatology, 2015, 14, 33-40.	0.4	26
16	Comparative Efficacy of Targeted Systemic Therapies for Moderate to Severe Atopic Dermatitis without Topical Corticosteroids: Systematic Review and Network Meta-analysis. Dermatology and Therapy, 2022, 12, 1181-1196.	1.4	24
17	Systematic Review on the Efficacy and Safety of Oral Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis. Frontiers in Medicine, 2021, 8, 682547.	1.2	20
18	Using the Internet to Assess and Teach Medical Students in Dermatology. Journal of Cutaneous Medicine and Surgery, 2002, 6, 315-319.	0.6	19

#	Article	IF	Citations
19	Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis and Prior Use of Systemic Non-Steroidal Immunosuppressants: Analysis of Four PhaseÂ3 Trials. Dermatology and Therapy, 2021, 11, 1357-1372.	1.4	19
20	Treating Psoriasis and Psoriatic Arthritis: Position Paper on Applying the Treat-to-target Concept to Canadian Daily Practice. Journal of Rheumatology, 2017, 44, 519-534.	1.0	18
21	A Treatment Algorithm for Moderate to Severe Atopic Dermatitis in Adults. Journal of Cutaneous Medicine and Surgery, 2018, 22, 78-83.	0.6	17
22	Management of Plaque Psoriasis With Biologic Therapies in Women of Child-Bearing Potential Consensus Paper. Journal of Cutaneous Medicine and Surgery, 2020, 24, 3S-14S.	0.6	16
23	Elastosis Perforans Serpignosa: Treatment with Liquid Nitrogen Cryotherapy and Review of the Literature. Journal of Cutaneous Medicine and Surgery, 2010, 14, 38-42.	0.6	13
24	Incidence of COVID-19 in Patients With Chronic Idiopathic Urticaria and Asthma on Omalizumab: A Multicentre Retrospective Cohort Study. Journal of Cutaneous Medicine and Surgery, 2022, 26, 319-320.	0.6	12
25	International eDelphi Study to Reach Consensus on the Methotrexate Dosing Regimen in Patients With Psoriasis. JAMA Dermatology, 2022, 158, 561.	2.0	12
26	Brodalumab success in patients with moderate-to-severe psoriasis who failed previous interleukin-17A inhibitors. Journal of the American Academy of Dermatology, 2021, 84, 1169-1171.	0.6	11
27	A randomized controlled study of combination therapy with alefacept and narrow band UVB phototherapy (UVB) for moderate to severe psoriasis: efficacy, onset, and duration of response. Journal of Drugs in Dermatology, 2012, 11, 929-37.	0.4	10
28	Approach to the Assessment and Management of Pediatric Patients With Atopic Dermatitis: A Consensus Document. Section IV: Consensus Statements on the Assessment and Management of Pediatric Atopic Dermatitis. Journal of Cutaneous Medicine and Surgery, 2019, 23, 32S-39S.	0.6	9
29	A Consensus on Acne Management Focused on Specific Patient Features. Journal of Cutaneous Medicine and Surgery, 2014, 18, 243-255.	0.6	6
30	Efficacy, tolerability, patient usability, and satisfaction with a 2 mL pre-filled syringe containing secukinumab 300 mg in patients with moderate to severe plaque psoriasis: results from the phase 3 randomized, double-blind, placebo-controlled ALLURE study. Journal of Dermatological Treatment, 2022, 33, 1718-1726.	1.1	6
31	Cutaneous Metastases from Non-Small Cell Lung Cancer. Journal of Cutaneous Medicine and Surgery, 2006, 10, 304-307.	0.6	5
32	Kikuchi—Fujimoto's Necrotizing Lymphadenitis in Association with Discoid Lupus Erthematosus: A Case Report. Journal of Cutaneous Medicine and Surgery, 2004, 8, 442-445.	0.6	4
33	89% Vichy mineralizing water with hyaluronic acid is a wellâ€tolerated adjunct treatment that helps restore skin barrier function in dry skinâ€related inflammatory dermatoses and postâ€procedure skin care: A Canadian study. Journal of Cosmetic Dermatology, 2021, 20, 2148-2155.	0.8	4
34	Approach to the Assessment and Management of Adult Patients With Atopic Dermatitis: A Consensus Document. Section III: Evaluation of Atopic Dermatitis Patients for Comorbidities. Journal of Cutaneous Medicine and Surgery, 2018, 22, 17S-20S.	0.6	3
35	Practical Management of Patients with Atopic Dermatitis on Dupilumab. Dermatology and Therapy, 2021, 11, 1805-1828.	1.4	3
36	Roflumilast Cream 0.3% Improved the Severity and Impact of Itch in Patients With Chronic Plaque Psoriasis in the Phase 3 DERMIS-1 and DERMIS-2 Studies. SKIN the Journal of Cutaneous Medicine, 2021, 5, s41.	0.1	3

3

#	Article	IF	Citations
37	Incidence and prognosis of COVID-19 in patients with atopic diseases on dupilumab: a multicentre retrospective cohort study. Journal of Dermatological Treatment, 2022, 33, 2692-2694.	1.1	3
38	Tapinarof Cream for the Treatment of Plaque Psoriasis: Efficacy and Safety by Baseline Disease Characteristics and Skin Type in a Phase 2b Randomized Study. SKIN the Journal of Cutaneous Medicine, 2020, 4, s30.	0.1	2
39	Practical and Relevant Guidelines for the Management of Psoriasis: An Inference-Based Methodology. Dermatology and Therapy, 2022, 12, 253-265.	1.4	2
40	Definition of Moderate to Severe Hidradenitis Suppurativa. Journal of Cutaneous Medicine and Surgery, 2016, 20, 613-615.	0.6	1
41	28032 Rapid itch improvement with upadacitinib with or without concomitant topical corticosteroids (TCS) in moderate-to-severe atopic dermatitis (AD): Results from 3 phase 3 studies (Measure Up 1,) Tj ETQq1 1 ().784314	rgBT /Overlo
42	Use of Systemic Therapies for Treatment of Psoriasis in People Living with Controlled HIV: Inference-Based Guidance from a Multidisciplinary Expert Panel. Dermatology and Therapy, 2022, 12, 1073-1089.	1.4	1
43	Efficacy of Dupilumab in Atopic Dermatitis: The Patient's Perspective. Dermatology and Therapy, 2021, 11, 2123-2131.	1.4	0